Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma

Cancer Gene Therapy

Volumn 22, Issue 1, 2015, Pages 1-8

  Hicks, M J ^a   Funato, K ^b   Wang, L ^a   Aronowitz, E ^a   Dyke, J P ^a   Ballon, D J ^a   Havlicek, D F ^a   Frenk, E Z ^a   De, B P ^a   Chiuchiolo, M J ^a   Sondhi, D ^a   Hackett, N R ^a   Kaminsky, S M ^a   Tabar, V ^b   Crystal, R G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GADOLINIUM PENTETATE MEGLUMINE; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SEQUENCE; GENE TRANSFER; GENE VECTOR; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; MOUSE; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VOLUMETRY; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETICS; METABOLISM; MORTALITY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ADENO-ASSOCIATED VIRUS; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEURONS; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921847272     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.58     Document Type: Article

References (50)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14 Suppl 5: v1-49.
4. Barker FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42: 709-720.
5. Allahdini F, Amirjamshidi A, Reza-Zarei M, Abdollahi M. Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival? World Neurosurg 2010; 73: 128-134.
6. Park JK, Hodges T, Arko L, Shen M, Dello ID, McNabb A et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010; 28: 3838-3843.
7. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
8. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008; 7: 2553-2561.
9. Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011; 76: 87-93.
10. Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 2011; 114: 624-632.
11. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009; 18: 1061-1083.
12. Jain RK, di TE, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610-622.
13. Sweet JA, Feinberg ML, Sherman JH. The role of avastin in the management of recurrent glioblastoma. Neurosurg Clin N Am 2012; 23: 331-341, x.
14. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29: 142-148.
15. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci 2012; 19: 1636-1640.
16. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007; 15: 481-491.
17. Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods 2012; 23: 324-335.
18. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463-474.
19. Souweidane MM, Fraser JF, Arkin LM, Sondhi D, Hackett NR, Kaminsky SM et al. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J Neurosurg Pediatr 2010; 6: 115-122.
20. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
21. Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010; 17: 1042-1051.
22. Mao Y, Kiss S, Boyer JL, Hackett NR, Qiu J, Carbone A et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther 2011; 22: 1525-1535.
23. Watanabe M, Boyer JL, Hackett NR, Qiu J. Crystal RG. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Hum Gene Ther 2008; 19: 300-310.
24. Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD et al. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther 2012; 23: 451-459.
25. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
26. Hasselbalch B, Lassen U, Poulsen HS. Patients with recurrent high-grade glioma: therapy with combination of bevacizumab and irinotecan. In: Hayat MA (eds). Tumors of the Central Nervous System. New York: Springer Science+Business Media, 2011; 289-299.
27. Hawkins-Daarud A, Rockne RC, Anderson AR, Swanson KR. Modeling tumorassociated edema in gliomas during anti-angiogenic therapy and its impact on imageable tumor. Front Oncol 2013; 3: 66.
28. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 2012; 23: 307-322 ix.
29. Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K et al. Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 2013; 31: 287-308.
30. Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs 2014; 23: 199-210.
31. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-620.
32. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694-705.
33. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71: 6073-6083.
34. Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011; 76: 432-437.
35. von BL, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011; 17: 6192-6205.
36. Ebos JM, Pili R. Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clin Cancer Res 2012; 18: 3719-3721.
37. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
38. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011; 104: 629-638.
39. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013;41: 33-39.
40. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
41. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14: 285-294.
42. Leveque D, Wisniewski S, Jehl F. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 2005; 25: 2327-2343.
43. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002; 81: 203-206.
44. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007; 29: 1850-1861.
45. Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009; 9: 507-517.
46. Langer C, Soria JC. The role of anti-epidermal growth factor receptor and antivascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 82-90.
47. Galfrascoli E, Piva S, Cinquini M, Rossi A, La VN, Bramati A et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 2011; 43: 286-294.
48. Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res 2010; 2: 97-104.
49. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-786.
50. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der HM, Moayedpardazi H et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010; 28: 1019-1029.